CYRANO THERAPEUTICS
Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significant improvement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program. Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA.
CYRANO THERAPEUTICS
Social Links:
Industry:
Health Care Medical Medical Device Therapeutics
Founded:
2014-01-01
Address:
Washington, District Of Columbia, United States
Country:
United States
Website Url:
http://www.cyranotherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
12.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default WordPress Apache Wordpress Plugins Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Remiges Ventures
Remiges Ventures investment in Series A - Cyrano Therapeutics
Lumira Ventures
Lumira Ventures investment in Series A - Cyrano Therapeutics
Official Site Inspections
http://www.cyranotherapeutics.com
- Host name: 244.0.153.160.host.secureserver.net
- IP address: 160.153.0.244
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Cyrano Therapeutics"
Smell Loss Therapy | Cyrano Therapeutics - The …
Olfactory dysfunction, or the loss or impairment of the sense of smell, affects millions worldwide. This condition, often caused by viral infections, head trauma, or neurodegenerative diseases, impacts more than just the ability to detect …See details»
Cyrano Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The …See details»
Cyrano Therapeutics - LinkedIn
Cyrano Therapeutics has developed a unique, proprietary intranasal formulation to restore function in patients with a chronic loss of taste and smell.See details»
Cyrano Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
View Cyrano Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Smell Loss Therapy Research - Cyrano Therapeutics
Taka Koda is Partner at Remiges Ventures, a US-Japan venture capital firm focusing on therapeutics. With over 20 years of business development and venture investment experience, …See details»
CYRANO THERAPEUTICS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CYRANO THERAPEUTICS, INC. of Delray Beach, FL. Get the latest business insights from Dun & …See details»
Investing in Regenerative Medicine - Cyrano Therapeutics
Remiges Ventures Based in Seattle and Tokyo, Remiges Ventures is a US-Japan cross-border venture capital firm focused on therapeutics. Remiges Ventures takes a lead position for the …See details»
Cyrano Therapeutics 2025 Company Profile: Valuation, …
Cyrano Therapeutics General Information Description. Developer of an intranasal spray therapy designed for chronic smell and taste loss due to a virus. The company's product comes with a diagnostic kit to diagnose and quantify the …See details»
Cyrano Therapeutics Management Team | Org Chart - RocketReach
Cyrano Therapeutics employs 7 employees. The Cyrano Therapeutics management team includes Rick Geoffrion (President & CEO), John Kollins (Member Board Of Directors), and …See details»
Cyrano Therapeutics - Overview, News & Similar companies
Cyrano Therapeutics contact info: Phone number: (925) 822-6461 Website: www.cyranotherapeutics.com What does Cyrano Therapeutics do? Cyrano Therapeutics is a …See details»
Cyrano Therapeutics Company Profile -Sales, Contacts ... - Buzzfile
Cyrano Therapeutics is located in Delray Beach, Florida. This organization primarily operates in the Drugs Acting On the Central Nervous System & Sense Organs business / industry within …See details»
Cyrano Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
To learn more, please visit cyranotherapeutics.com. About the FLAVOR Trial The Phase 2 FLAVOR trial is a 150 subject randomized, double-blinded, placebo-controlled, multi-dose, …See details»
Cyrano Therapeutics - VentureRadar
Website: https://cyranotherapeutics.com/ Develops therapies for individuals experiencing long-term smell and flavor loss, a condition affecting millions in the US pre ...See details»
Cyrano Therateutics - Remiges Ventures
Dec 10, 2020 Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company developing a novel therapy to restore smell and flavor function.See details»
Cyrano Therapeutics - Products, Competitors, Financials, …
Cyranotherapeutics.com. Overview & Products; Financials; People; Founded Year 2014. Stage Series B | Alive. Total Raised $21.8M. Last Raised $9M | 1 yr ago. About Cyrano …See details»
KYORIN and Cyrano Therapeutics Partner to Advance CYR-064
Feb 18, 2025 To learn more, please visit cyranotherapeutics.com. 1. Clinical practice guidelines for olfactory dysfunction (The Japanese rhinologic society) Japanese Journal of Rhinology …See details»
Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR …
Oct 12, 2023 For more information, please visit cyranotherapeutics.com. SOURCE Cyrano Therapeutics. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? …See details»
Cyrano Therapeutics and Resyca Announce Exclusive License …
5 days ago To learn more, please visit cyranotherapeutics.com. About Resyca Resyca® was founded in 2020 and is a joint venture between Bespak and Medspray. Resyca® specialises in …See details»
First Patient in Smell Loss; Cyrano Therapeutics begins Enrollment
There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition. Delray Beach, FL, October 12, 2023 – Cyrano Therapeutics, Inc., a …See details»
Mission, Vision & Core Values of Cyrano Therapeutics
Dec 19, 2024 [cbm_blg_rlnkng]Cyrano Therapeutics Mission, Vision & Core Values Cyrano Therapeutics is a cutting-edge biotechnology company dedicated to revolutionizing the way we …See details»